Stocks
Merck Stock Hits New All-Time High Amid Strong Performance
MERCK stock has hit an all-time high of $153.53, representing a 74.34% surge over the past year.
The pharmaceutical giant's strong financial results and strategic initiatives have contributed to investor confidence, driving its stock to this new peak.
In related news, Merck announced positive Phase 3 trial results with Moderna for treating Stage IIB-IV melanoma, marking a significant milestone in mRNA cancer therapy. Guggenheim reiterated a Buy rating for Merck, while UBS downgraded the company to neutral due to its current valuation.